Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early‐stage non‐small‐cell lung cancer: a population‐based study
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15404 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Hung-Jen Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery, Dose Fractionation, Radiation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical University Hospital.
Abstract (Originalsprache)
Introduction
The use of stereotactic ablative radiotherapy (SABR) over conventional fractionated radiotherapy (CFRT) for early‐stage non‐small‐cell lung cancer (NSCLC) has been advocated, but is also debated in the literature.
Methods
In this retrospective cohort study, we adopted a target trial emulation framework to identify eligible patients diagnosed between 2011 and 2021 using the Taiwan Cancer Registry. In the primary analysis, the overall survival (OS) was the primary endpoint, whereas incidences of lung cancer mortality and radiation pulmonary toxicity were the secondary endpoints. Extensive supplementary analyses were also conducted.
Results
We included 351 patients in the primary analysis and found that the OS was not significantly different between the SABR ( n = 290) and CFRT ( n = 61) groups. The propensity score weighting adjusted hazard ratio of death was 0.75 (95% confidence interval 0.53–1.07, p = 0.118). The secondary endpoints and supplementary analyses showed no significant differences.
Conclusions
The OS of patients with early‐stage NSCLC treated with SABR was not significantly different from that of patients treated with CFRT alone. The results of the relevant ongoing clinical trials are eagerly awaited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
- School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
- Ph.D. Program for Health Science and Industry, College of Health Care, China Medical University, Taichung, Taiwan.
- Department of Chest Surgery, China Medical University Hospital, Taichung, Taiwan.
- Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan.
ORCID-Profile: Chun-Ru Chien
Förderung
- China Medical University Hospital
Zitieren
APA
Chen, H. J., Cheng, W. C., Tu, C. Y., Hsia, T. C., Lin, Y. S., Fang, H. Y., Li, C. C., & Chien, C. R. (2024). Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early‐stage non‐small‐cell lung cancer: a population‐based study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15404
Vancouver
Chen HJ, Cheng WC, Tu CY, Hsia TC, Lin YS, Fang HY, et al. Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early‐stage non‐small‐cell lung cancer: a population‐based study. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15404
BibTeX
@article{Chen2024,
author = {Chen, Hung-Jen and Cheng, Wen-Chien and Tu, Chih-Yen and Hsia, Te-Chun and Lin, Yu-Sen and Fang, Hsin-Yuan and Li, Chia-Chin and Chien, Chun-Ru},
title = {Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early‐stage non‐small‐cell lung cancer: a population‐based study},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15404}
}
EUVIMED